EGFR+ Lung Cancer

Clinical Approach for Unresectable Locally Advanced NSCLC

According to the results from a phase I study, BLU-667, a next-generation tyrosine kinase inhibitor, was well-tolerated and demonstrated clinical benefit in patients with advanced,&nbsp;<em>RET</em>-altered solid tumors who had progressed on previous therapies. These findings were presented April 14 to 18 at the ASCR Annual Meeting 2018 in Chicago, Illinois.

Similar improvements in quality of life were found with frontline treatment of osimertinib for patients with&nbsp;advanced&nbsp;EGFR-mutant non&ndash;small cell lung cancer, as well as&nbsp;a clinically meaningful improvement in cough, compared with the standard-of-care EGFR TKIs, according to the phase III FLAURA trial. The results were presented at the 2018 European Lung Cancer Congress&nbsp;in Geneva, Switzerland.

EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases

According to findings presented by Martin Reck, MD, PhD, at the 2018 European Lung Cancer Conference, the frontline regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel has became a potential new standard of care for the treatment of patients with metastatic nonsquamous non&ndash;small cell lung cancer.

EGFR+ NSCLC

According to 3-year survival findings from the phase II POPLAR study,&nbsp;anti PD-L1 immunotherapy with atezolizumab (Tecentriq) demonstrated strong superiority to&nbsp;docetaxel in locally advanced or metastatic non&ndash;small cell lung cancer.

Overall survival was improved with the&nbsp;PD-1 inhibitor pembrolizumab versus chemotherapy as a frontline treatment for patients with&nbsp;locally advanced or metastatic non&ndash;small cell lung cancer and a PD-L1 expression level &ge;1%, according to findings from the phase III KEYNOTE-042 trial.<br /> &nbsp;